Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
Akeso's Ivonescimab Secures Breakthrough Therapy Designation Akeso announced that its bispecific antibody, ivonescimab, has secured a Breakthrough Therapy Designation in China for first-li…